Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia

Alferez,Denis  G.; Goodlad,Robert  A.; Odedra,Rajesh; Sini,Patrizia; Crafter,Claire; Ryan,Anderson  J.; Wedge,Stephen  R.; Wright,Nicholas   A.; Anderson,Elizabeth; Wilkinson,Robert  W.

doi:10.3892/ijo.2012.1580

Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia

Authors:
- Denis G. Alferez
- Robert A. Goodlad
- Rajesh Odedra
- Patrizia Sini
- Claire Crafter
- Anderson J. Ryan
- Stephen R. Wedge
- Nicholas A. Wright
- Elizabeth Anderson
- Robert W. Wilkinson
View Affiliations

Affiliations: Histopathology Unit, London Research Institute, Cancer Research UK, Lincoln's Inn Fields, London, UK, Oncology iMED, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, UK
Published online on: July 31, 2012 https://doi.org/10.3892/ijo.2012.1580
Pages: 1475-1485

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Aurora family of kinases, play a fundamental role in cell division and are overexpressed in several cancers including colon. The activity of barasertib-hQPA, a selective inhibitor of Aurora-B kinase (ABK) was investigated in a range of preclinical models of gastrointestinal cancer. Treatment with barasertib-hQPA produced anti-proliferative and cytotoxic effects across a panel of human colorectal cancer (CRC) cell lines in vitro. Prodrug, barasertib [48-h subcutaneous (s.c.) infusion; 150 mg/kg/day] inhibited the growth of SW620, Colo205, HCT116 human colorectal tumor xenografts in nude mice significantly (Student's t-test, P<0.05, n=10-12 per group). Flow cytometric analysis of single cells from disaggregated barasertib-treated SW620 tumors revealed a decrease in phosphorylated histone H3 (phH3) and an increase in tumor cells with ≥4N DNA content P<0.05). The activity of barasertib was then examined in ApcMin/+ mice, a spontaneous model of early intestinal neoplasia. Macroscopic evaluation of the small intestine revealed that barasertib treatment [25 mg/kg intra-peritoneal (i.p.) Q1Dx4 each week for 3 weeks] of 8-week old ApcMin/+ mice produced a 39% reduction in macroadenoma number (P=0.02) and a 43% reduction in overall adenoma burden (P=0.02) compared with vehicle-treated controls. Quantification of microscopic adenomas revealed a >64% reduction in the number of adenomas spanning more than one villus. Histological analysis of these adenomas revealed a number of distinct changes in barasertib-treated ApcMin/+ mice, including a 94% reduction in the proportion of phospho-histone H3-positive cells (P<0.001) and a 53% reduction in the number of cells per adenoma (P=0.001). These results provide a scientific rationale for investigating ABK inhibitors as a treatment for intestinal cancer.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2	Chee CE and Sinicrope FA: Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am. 39:601–613. 2010. View Article : Google Scholar : PubMed/NCBI
3	Keen N and Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 4:927–936. 2004. View Article : Google Scholar : PubMed/NCBI
4	Yang KT, Li SK, Chang CC, et al: Aurora-C kinase deficiency causes cytokinesis failure in meiosis I and production of large polyploid oocytes in mice. Mol Biol Cell. 21:2371–2383. 2010. View Article : Google Scholar : PubMed/NCBI
5	Bischoff JR, Anderson L, Zhu Y, et al: A homologue of Drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998. View Article : Google Scholar : PubMed/NCBI
6	Pohl A, Azuma M, Zhang W, et al: Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J. 11:93–99. 2011. View Article : Google Scholar : PubMed/NCBI
7	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
8	Ilyas M, Straub J, Tomlinson IP and Bodmer WF: Genetic pathways in colorectal and other cancers. Eur J Cancer. 35:1986–2002. 1999. View Article : Google Scholar
9	Senda T, Iizuka-Kogo A, Onouchi T and Shimomura A: Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia. Med Mol Morphol. 40:68–81. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hanson CA and Miller JR: Non-traditional roles for the Adenomatous Polyposis Coli (APC) tumor suppressor protein. Gene. 361:1–12. 2005. View Article : Google Scholar : PubMed/NCBI
11	Boman BM, Walters R, Fields JZ, et al: Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population. Am J Pathol. 165:1489–1498. 2004. View Article : Google Scholar
12	Zhang T, Fields JZ, Opdenaker L, et al: Survivin-induced Aurora-B kinase activation: A mechanism by which APC mutations contribute to increased mitoses during colon cancer development. Am J Pathol. 177:2816–2826. 2010. View Article : Google Scholar
13	Wilkinson RW, Odedra R, Heaton SP, et al: AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 13:3682–3688. 2007. View Article : Google Scholar : PubMed/NCBI
14	Preston S, Leedham S, Oukrif D, et al: The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse. J Pathol. 214:294–301. 2008. View Article : Google Scholar : PubMed/NCBI
15	Minde DP, Anvarian Z, Rüdiger SG and Maurice MM: Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? Mol Cancer. 10:1012011. View Article : Google Scholar : PubMed/NCBI
16	Chen LC, Hao CY, Chiu YS, et al: Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res. 64:3694–3700. 2004. View Article : Google Scholar : PubMed/NCBI
17	Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer. 41:1911–1922. 2005. View Article : Google Scholar : PubMed/NCBI
18	Mortlock AA, Foote KM, Heron NM, et al: Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem. 50:2213–2224. 2007. View Article : Google Scholar : PubMed/NCBI
19	Cummings J, Hodgkinson C, Odedra R, et al: Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther. 7:455–463. 2008. View Article : Google Scholar : PubMed/NCBI
20	Wedge SR, Ogilvie DJ, Dukes M, et al: ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 60:970–975. 2000.
21	Widrow RJ, Rabinovitch PS, Cho K and Laird CD: Separation of cells at different times within G2 and mitosis by cyclin B1 flow cytometry. Cytometry. 27:250–254. 1997. View Article : Google Scholar
22	Alferez D, Ryan A, Goodlad R, Wright N and Wilkinson R: Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc^MIN/+ mouse model. Int J Oncol. 37:767–772. 2010. View Article : Google Scholar : PubMed/NCBI
23	Alferez D, Wilkinson RW, Watkins J, et al: Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. Mol Cancer Ther. 7:590–598. 2008.PubMed/NCBI
24	Goodlad RA, Ryan AJ, Wedge SR, et al: Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis. 27:2133–2139. 2006.PubMed/NCBI
25	Alferez D and Goodlad R: To best measure cell proliferation in samples from the intestine. Cell Prolif. 40:231–240. 2007. View Article : Google Scholar : PubMed/NCBI
26	Nair JS, Ho AL, Tse AN, et al: Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell. 20:2218–2228. 2009. View Article : Google Scholar : PubMed/NCBI
27	Ditchfield C, Johnson VL, Tighe A, et al: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol. 161:267–280. 2003. View Article : Google Scholar : PubMed/NCBI
28	Ota T, Suto S, Katayama H, et al: Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 62:5168–5177. 2002.PubMed/NCBI
29	Lens SM, Voest EE and Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer. 10:825–841. 2010. View Article : Google Scholar : PubMed/NCBI
30	Oke A, Pearce D, Wilkinson RW, et al: AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 69:4150–4158. 2009. View Article : Google Scholar : PubMed/NCBI
31	Aihara A, Tanaka S, Yasen M, et al: The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 52:63–71. 2010. View Article : Google Scholar : PubMed/NCBI
32	Nair JS, de Stanchina E and Schwartz GK: The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res. 15:2022–2030. 2009. View Article : Google Scholar : PubMed/NCBI
33	Azzariti A, Bocci G, Porcelli L, et al: Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer. 104:769–780. 2011. View Article : Google Scholar : PubMed/NCBI
34	Grundy M, Seedhouse C, Russell NH and Pallis M: P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer. 11:2542011. View Article : Google Scholar : PubMed/NCBI
35	Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, et al: Assessment of the in vivo antitumor effects of ENMD-2076, a novel multi-targeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res. 16:2989–2998. 2010. View Article : Google Scholar
36	Girdler F, Gascoigne KE, Eyers PA, et al: Validating Aurora B as an anti-cancer drug target. J Cell Sci. 119:3664–3675. 2006. View Article : Google Scholar : PubMed/NCBI
37	Boivin GP, Washington K, Yang K, et al: Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology. 124:762–777. 2003. View Article : Google Scholar : PubMed/NCBI
38	Paulsen JE: Modulation by dietary factors in murine FAP models. Toxicol Lett. 112–113:403–409. 2000.PubMed/NCBI
39	Rhodes JM and Campbell BJ: Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 8:10–16. 2002. View Article : Google Scholar : PubMed/NCBI
40	Alison M: The Cancer Handbook. John Wiley & Sons, Chichester; West Sussex, Hoboken, NJ: 2007
41	Boss DS, Witteveen PO, van der Sar J, et al: Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 22:431–437. 2011. View Article : Google Scholar : PubMed/NCBI